Gough SM, Flanagan JJ, Teh J, Andreoli M, et al. Oral estrogen receptor PROTAC(R) vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res 2024 May 31. doi: 10.1158/1078-0432.CCR-23-3465.
PMID: 38819400